title: [Synchronous chromophobe renal carcinoma and centrocytic lymphoma].
abstract: OBJECTIVE
  To report a case of synchronic neoplasia--chromophobe renal cell carcinoma and low grade non Hodgkin lymphoma--in a 38-year-old male patient, because, although association of these two neoplasias is known, the fact of renal neoplasia being a chromophobe carcinoma is rarely referred to in medical bibliography (3 cases described after Med-Line search).
  
  
  RESULTS
  The diagnostic study included ultrasound and CT scan in a patient presenting with in non specific abdominal symptoms and neck adenopathy; patient underwent left radical nephrectomy and excision of neck adenopathy. Histologic and immuno-histochemical studies revealed the coexistence of chromophobe type renal cell carcinoma and diffuse centrocytic lymphoma.
  
  
  CONCLUSIONS
  Column in the association between chromophobe histological type renal cell carcinoma and non Hodgkin lymphoma is very rare. Presence of these two tumors in the same patient may pose problems for clinical staging, prognostic predictions, and treatment. Then, due to the fact that it is not usual and that a local stage renal carcinoma presents with neck adenopathies, when they appear possible coexistence of these tumors should be suspected.
authors.affiliation: Servicios de Radiodiagnóstico, Hospital Clínico Universitario, Málaga, España.
authors.forename: Antonio Javier
authors.initials: AJ
authors.lastname: Márquez Moreno
authors.forename: Jorge
authors.initials: J
authors.lastname: Mañas Uxó
authors.forename: Francisco
authors.initials: F
authors.lastname: Amores Ramírez
authors.forename: Rafael
authors.initials: R
authors.lastname: Aguilar Cuevas
authors.forename: María Victoria
authors.initials: MV
authors.lastname: Ortega Jiménez
authors.forename: Carmen
authors.initials: C
authors.lastname: Leiva Vera
authors.forename: Diego
authors.initials: D
authors.lastname: Pérez Rodríguez
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D002292:Carcinoma, Renal Cell / Q000175:diagnosis / Q000188:drug therapy / Q000473:pathology* / Q000601:surgery; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D006801:Humans; D007680:Kidney Neoplasms / Q000175:diagnosis / Q000188:drug therapy / Q000473:pathology* / Q000601:surgery; D020522:Lymphoma, Mantle-Cell / Q000175:diagnosis / Q000188:drug therapy / Q000473:pathology* / Q000601:surgery; D008228:Lymphoma, Non-Hodgkin / Q000175:diagnosis / Q000188:drug therapy / Q000473:pathology* / Q000601:surgery; D008297:Male; D009378:Neoplasms, Multiple Primary / Q000175:diagnosis / Q000188:drug therapy / Q000473:pathology* / Q000601:surgery; D009392:Nephrectomy; D011241:Prednisone / Q000008:administration & dosage; D014057:Tomography, X-Ray Computed; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone